Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis

NCT00832208 is registered in ClinicalTrials.gov with Drugs for Neglected Diseases as lead sponsor.

NCT NCT00832208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00832208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis
Lead sponsor
Drugs for Neglected Diseases
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2009
Completion date
March 31, 2011
Enrollment
124 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

visceral leishmaniasis